do glp 1 reduce cancer risk GLP-1 drugs may in obese adults | Dr Rishabh Jain posted on the topic Ozempic, Wegovy: GLP-1 Drugs Lower

Diagnostics (Basel, Switzerland) 15 , 580 (2025)

Enter John Eng, a physician-researcher working at the James J

Growing use of GLP-1 receptor agonists for obesity and Type 2 Diabetes Mellitus (T2DM) has highlighted their effects on skin, hair, and nails

Real users consistently report rebound hunger and no sustained weight loss

Novo Nordisks once-daily oral Wegovy (25 mg semaglutide) is now approved for adults with obesity, or overweight patients with at least one weight-related condition, marking the first pill-based GLP-1 option indicated for both weight loss and cardiovascular risk reduction

The compounded tirzepatide starting dose typically mirrors this same gradual approach